The initial reporter also notified the fda.Medwatch report # mw5110470.Investigation summary: the customer issued a complaint for pre-activated problem detected by end user.No sample was provided to bdm-ps for analysis; therefore, it is not possible to investigate the reported condition.Bdm-ps did not perform a batch history record¿s review (bhr) as batch number of the device is unknown.Based on investigation conclusion, bdm-ps was not able to confirm the symptom perceived by customer or correlate this symptom with a potential cause linked to bd process.Based on investigation conclusion, bdm-ps was not able to confirm the symptom perceived by customer or correlate this symptom with a potential cause linked to bd process.During the years of investigation of complaints about pre-activated devices several root causes were discovered which were within the customer¿s sphere of influence.Best practices and guidelines were collected and summarized in 442.Cdfm.010.
|
It was reported that prior to use the bd ultrasafe plus¿ was unusable resulting in a need for medial intervention.The following information was provided by the initial reporter: patient received ziextenzo from a mail order pharmacy.When medication box was opened, safety needle mechanism had been previously engaged, causing medication to be unusable, as needle could not be re-extended and medication cannot be administered after mechanism engaged.Patient diagnosed with malignancy, using ziextenzo for prevention of prolonged neutropenia.Patient admitted to the hospital 6 days later for fever and neutropenia.
|